iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Gland Pharma announces launch of Bortezomib for Injection in US market

7 May 2022 , 01:33 AM

Gland Pharma through its partner has launched Bortezomib for Injection 35 mgvial Single-Dose Vial in the US Market It is the bioequivalent and therapeutically equivalent to thereference listed drug RLD Velcade for Injection 35 mgvial of Takeda Pharmaceuticals USA Inc Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma Velcade has a market size of USD 1172 million for the twelve months ending March 2022 according to IQVIA Gland Pharmas partner has received the ANDA approval for the product from US Food Drug Administration US FDA Gland Pharma is manufacturing and supplying this product to its partner for the US market

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.